[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549432":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":11,"locations":31,"responsibleParty":215,"collaborators":11,"id":217,"slug":218,"hasResults":219,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":11,"eligibilityCriteria":223,"healthyVolunteers":219,"sex":224,"minAge":225,"maxAge":11,"enrollmentInfo":226,"targetDuration":11,"studyType":229,"phases":230,"briefSummary":232,"conditions":233,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},{"fullName":5,"class":6},"Opna Bio LLC","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose escalation monotherapy","EXPERIMENTAL",null,[13],"Drug: OPN-6602",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose escalation in combo with dexamethasone",[13,17],"Drug: Dexamethasone",{"label":19,"type":10,"description":11,"interventionNames":20},"Dose expansion",[13],[22,27],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","OPN-6602","orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily",[15,9,19],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Dexamethasone","Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle",[15],[32,52,67,81,96,111,126,141,155,170,185,200],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Banner MD Anderson","RECRUITING","Gilbert","Arizona","85234","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-111.78903,33.35283,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Brett Post","CONTACT","480-256-3116","brett.post@bannerhealth.com",{"facility":53,"status":34,"city":54,"state":55,"zip":56,"country":38,"countryCode":39,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"UC San Diego Moores Cancer Center","La Jolla","California","92093-0698",{"type":41,"coordinates":58},[59,60],-117.2742,32.84727,{"lat":60,"lon":59},[63],{"name":64,"role":49,"phone":65,"phoneExt":11,"email":66},"Rebecca Jimenez","858-822-5377","rejimenez@health.ucsd.edu",{"facility":68,"status":34,"city":69,"state":55,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Stanford Cancer Institute","Stanford","94305",{"type":41,"coordinates":72},[73,74],-122.16608,37.42411,{"lat":74,"lon":73},[77],{"name":78,"role":49,"phone":79,"phoneExt":11,"email":80},"Caitlyn Minas","650-723-0646","cminas@stanford.edu",{"facility":82,"status":34,"city":83,"state":84,"zip":85,"country":38,"countryCode":39,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Emory Winchip Cancer Center","Atlanta","Georgia","30322",{"type":41,"coordinates":87},[88,89],-84.38798,33.749,{"lat":89,"lon":88},[92],{"name":93,"role":49,"phone":94,"phoneExt":11,"email":95},"Megan Marshall","404-778-5204","megan.marshall@emory.edu",{"facility":97,"status":34,"city":98,"state":99,"zip":100,"country":38,"countryCode":39,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"University of Kansas Clinical Research Center","Westwood","Kansas","66205",{"type":41,"coordinates":102},[103,104],-94.6169,39.04056,{"lat":104,"lon":103},[107],{"name":108,"role":49,"phone":109,"phoneExt":11,"email":110},"Nurse Navigation","913-945-7552","CTNurseNav@kumc.edu",{"facility":112,"status":34,"city":113,"state":114,"zip":115,"country":38,"countryCode":39,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":41,"coordinates":117},[118,119],-71.05977,42.35843,{"lat":119,"lon":118},[122],{"name":123,"role":49,"phone":124,"phoneExt":11,"email":125},"Yuxin Liu","877-422-3324","yuxin_liu@dfci.harvard.edu",{"facility":127,"status":34,"city":128,"state":129,"zip":130,"country":38,"countryCode":39,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":41,"coordinates":132},[133,134],-83.04575,42.33143,{"lat":134,"lon":133},[137],{"name":138,"role":49,"phone":139,"phoneExt":11,"email":140},"Kate Staub","313-576-8736","staubk@karmanos.org",{"facility":142,"status":34,"city":143,"state":129,"zip":144,"country":38,"countryCode":39,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"START Midwest","Grand Rapids","49546",{"type":41,"coordinates":146},[147,148],-85.66809,42.96336,{"lat":148,"lon":147},[151],{"name":152,"role":49,"phone":153,"phoneExt":11,"email":154},"Julie Burns","616-954-5559","Julie.burns@startresearch.com",{"facility":156,"status":34,"city":157,"state":158,"zip":159,"country":38,"countryCode":39,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"University of Rochester Medical Center","Rochester","New York","14642",{"type":41,"coordinates":161},[162,163],-77.61556,43.15478,{"lat":163,"lon":162},[166],{"name":167,"role":49,"phone":168,"phoneExt":11,"email":169},"Liu","585-275-5823","wcicto@urmc.rochester.edu",{"facility":171,"status":34,"city":172,"state":173,"zip":174,"country":38,"countryCode":39,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"University of North Carolina Hospitals at Hillsborough","Chapel Hill","North Carolina","27599",{"type":41,"coordinates":176},[177,178],-79.05584,35.9132,{"lat":178,"lon":177},[181],{"name":182,"role":49,"phone":183,"phoneExt":11,"email":184},"Brice Messenger, CCRP","919-966-4432","brice_messenger@med.unc.edu",{"facility":186,"status":34,"city":187,"state":188,"zip":189,"country":38,"countryCode":39,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Huntsman Cancer Center Institute University of Utah","Salt Lake City","Utah","84112",{"type":41,"coordinates":191},[192,193],-111.89105,40.76078,{"lat":193,"lon":192},[196],{"name":197,"role":49,"phone":198,"phoneExt":11,"email":199},"Collind Boyington","801-587-4779","collind.boyington@hci.utah.edu",{"facility":201,"status":34,"city":202,"state":203,"zip":204,"country":38,"countryCode":39,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":41,"coordinates":206},[207,208],-122.33207,47.60621,{"lat":208,"lon":207},[211],{"name":212,"role":49,"phone":213,"phoneExt":11,"email":214},"Danai Dima","855-557-0555","ddima@fredhutch.org",{"type":216,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100549432","phase-1-study-to-assess-safety-and-tolerability-of-opn-6602-in-subjects-with-relapsed-andor-refractory-multiple-myeloma-100549432",false,"NCT06433947","Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1b, Dose Escalation\u002FDose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Confirmed diagnosis of multiple myeloma (MM)\n* Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody and not a candidate for or intolerant to established therapy known to provide clinical benefit\n* Adequate hematologic, renal, liver, cardiac function\n\nExclusion Criteria:\n\n* Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenström's macroglobulinemia, or IgM myeloma\n* Active plasma cell leukemia\n* Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS syndrome)\n* Prior Stevens Johnson syndrome\n* Localized radiation therapy to disease site(s) within 2 weeks of the first dose\n* Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within \\\u003C90 days of the first dose of study drug\n* Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of first dose of study drug; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.\n* Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug\n* Concomitant high-dose corticosteroids (except subjects on chronic steroids given for disorders other than myeloma)\n* Known central nervous system involvement by multiple myeloma\n* Active known second malignancy with exception of adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; adequately treated Stage 1 cancer from which the subject is currently in remission and has been in remission for ≥2 years; low-risk prostate cancer with a Gleason score \\\u003C7 and a PSA level \\\u003C10 ng\u002FmL; any other cancer from which the subject has been disease-free for ≥3 years\n* Ongoing systemic infection requiring parenteral treatment\n* Poorly controlled Type 2 diabetes","ALL","18 Years",{"count":227,"type":228},130,"ESTIMATED","INTERVENTIONAL",[231],"PHASE1","Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and\u002For refractory MM.",[234,235],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","2026-05-15",{"date":238,"type":239},"2026-05-19","ACTUAL",{"date":241,"type":239},"2024-08-22",{"date":243,"type":228},"2026-07",{"name":5,"class":6},12]